spacer
home > ebr > winter 2002 > personal genomes
PUBLICATIONS
European Biopharmaceutical Review

Personal Genomes

Recently, Dr Craig Venter created a stir by announcing that he was, for the princely sum of half a million dollars, providing the opportunity for high net worth individuals (presumably!) to have their whole genome sequenced. In fact, Dr Venter is interested from a scientific standpoint in acquiring comprehensive information about genetic variation in a number of individuals. It is a neat way of funding this endeavour if the individuals are prepared to pay for the activity themselves. But what would they gain for their money? Will useful information be provided or is this just another trophy purchase? Who gets the most out of this unusual contract? The view of some commentators has been that the CD containing their genetic code that these wealthy individuals will receive will have little more than novelty value. They argue that our understanding of the genome is so rudimentary that little interpretative value can be extracted at this stage.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Nick McCooke, Chief Executive Officer of Solexa

Nick McCooke, Chief Executive Officer of Solexa, was formerly President of Seattle-based genomics company Rapigene (now part of Qiagen NV), which under his leadership built one of the world's first fully operational high-throughput genotyping facilities.

From 1991 to 1998, he held a number of general management positions at Innovex (now part of Quintiles) including President of Innovex Japan, with responsibility for setting up a successful business based in Tokyo. Previously Nick worked for the UK biotech company, Celltech, in a number of commercial and general management roles. He holds a BSc and MSc in Engineering and an MBA from the London Business School.

spacer
Nick McCooke
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinsonís disease treatment

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
More info >>

White Papers

Competitive Drive: The Challenges of a Globalised Packaging Industry

Aesica Pharmaceuticals

Packaging is becoming an increasingly competitive and lucrative industry globally. Jeremy Drummond PhD of Aesica Formulated Products looks at the challenges and opportunities this presents.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement